Review details current practices, advantages, and challenges of regulatory data mining at the FDA, highlighting strategic opportunities for future post-market surveillance.
Topics include routine and developmental data mining activities, short descriptions of mined FDA data, advantages and challenges of data mining at the FDA, and future directions of data mining at the FDA.
No takes yet. Share an insight, caveat, or question.
Duggirala et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: